HOTH - Hoth Therapeutics surges on preclinical data for cancer therapy

Hoth Therapeutics (NASDAQ:HOTH) has gained ~135% in the pre-market Monday after the development-stage pharmaceutical company announced encouraging preclinical data for its investigational cancer therapy, HT-KIT. According to the company, a team of researchers who were part of a scientific research agreement with North Carolina State University found that KIT protein expression, signaling, and function reduced in response to HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro. “Our next round of preclinical studies are underway and we are excited to utilize the results for our planned Pre-IND meeting with FDA later this year," Chief Executive Robb Knie said. This is a developing story. Check back for more updates.

For further details see:

Hoth Therapeutics surges on preclinical data for cancer therapy